Back HCV Treatment Treatment Guidelines

HCV Treatment Guidelines

New Hepatitis C Guidelines: Who Should Be Treated and When?

Everyone with chronic hepatitis C could potentially benefit from treatment with new direct-acting antivirals, but when resources are limited, people with advanced liver disease, those at greatest risk for complications, and those most likely to transmit HCV should be treated most urgently, according to new guidelines released this week from AASLD, IDSA, and IAS-USA.

alt

Read more:

EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C, which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals. The guidelines also recommend physicians should "mix and match" antivirals from different companies to get the most potent regimens.

alt

Read more:

Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]

As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.

alt

Read more:

EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions

The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for HCV genotypes 1, 2, 3, and 4, or simeprevir (Olysio) with pegylated interferon interferon and ribavirin for genotype 1 infection. The WHO guidelines were released to coincide with the 49th International Liver Congress this week in London. New guidelines from the European Association for the Study of the Liver (EASL) will be released on Saturday.

alt

Read more:

CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients

An all-oral combination of the HCV protease inhibitor MK-5172 and the NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in HIV/HCV coinfected patients and high cure rates in people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent conferences.

alt

Read more: